Cancer vaccines and vaccination methods

Patent metadata

Field	Value
Publication number	US-9433667-B2
Application number	US-201113327125-A
Country	US
Kind code	B2
Filing date	Dec 15, 2011
Priority date	Sep 28, 2006
Publication date	Sep 6, 2016
Grant date	Sep 6, 2016

Abstract

Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.

First claim

What is claimed is:

1. A composition comprising dendritic cells, wherein the dendritic cells present on human leukocyte antigen (HLA) on their surface peptide epitopes, wherein the peptide epitopes are each 9 to 13 amino acids length and comprise the following six amino acid sequences:

(SEQ ID NO: 3)

RSDSGQQARY from AIM-2;

(SEQ ID NO: 4)

EADPTGHSY from MAGE-1;

(SEQ ID NO: 5)

SVYDFFVWL from TRP-2;

(SEQ ID NO: 67)

IMDQVPFSV, a superagonist peptide from gp100;

(SEQ ID NO: 37)

VMAGVGSPYV from HER-2;

and

(SEQ ID NO: 8)

WLPFGFILI from IL-13 receptor α2,

wherein the dendritic cells acquired the peptide epitopes in vitro by exposure to synthetic peptides comprising the peptide epitopes.

2. The composition of claim 1 , wherein the peptide epitopes comprise an HLA epitope from at least one antigen other than TRP-2, MAGE-1, HER-2, IL-13 receptor α2, gp100, and AIM2.

3. The composition of claim 1 , wherein the composition comprises between 10 5 and 10 8 dendritic cells.

4. The composition of claim 1 , wherein the composition comprises autologous dendritic cells.

5. The composition of claim 1 , wherein the composition comprises allogeneic dendritic cells.

6. The composition of claim 1 , wherein the dendritic cells present on HLA on their surface peptide epitopes of 9 or 10 amino acids in length.

7. The composition of claim 1 , wherein the peptide epitopes consist of the following six amino acid sequences:

(SEQ ID NO: 3)

RSDSGQQARY from AIM-2;

(SEQ ID NO: 4)

EADPTGHSY from MAGE-1;

(SEQ ID NO: 5)

SVYDFFVWL from TRP-2;

(SEQ ID NO: 67)

IMDQVPFSV, a superagonist peptide from gp100;

(SEQ ID NO: 37)

VMAGVGSPYV from HER-2;

and

(SEQ ID NO: 8)

WLPFGFILI from IL-13 receptor α2.

8. A process comprising:
obtaining bone marrow derived mononuclear cells from a patient,
culturing the mononuclear cells in vitro under conditions in which mononuclear cells become adherent to a culture vessel,
selecting a subset of the mononuclear cells comprising adherent cells,
culturing the adherent cells in the presence of one or more cytokines under conditions in which the cells differentiate into antigen presenting cells,
culturing the antigen presenting cells in the presence of synthetic peptides of the following six antigens: TRP-2, MAGE-1, HER-2, IL-13 receptor α2, gp100, and AIM2, wherein the synthetic peptides are each 9 to 13 amino acids in length and comprise the following six amino acid sequences:

(SEQ ID NO: 3)

RSDSGQQARY from AIM-2;

(SEQ ID NO: 4)

EADPTGHSY from MAGE-1;

(SEQ ID NO: 5)

SVYDFFVWL from TRP-2;

(SEQ ID NO: 67)

ITDQVPFSV, a superagonist peptide from gp100;

(SEQ ID NO: 37)

KIFGSLAFL from HER-2;

and

(SEQ ID NO: 8)

WLPFGFILI from IL-13 receptor α2,

under conditions in which the antigen presenting cells present the peptides on human leukocyte antigen (HLA), wherein the antigen presenting cells are dendritic cells.

9. The process of claim 8 , wherein the bone marrow derived cells are obtained from a patient with a glioma.

10. The process of claim 8 , wherein the antigen presenting cells are cultured in the presence of a synthetic peptide from at least one antigen other than TRP-2

Assignees

• Yu John S
• Liu Gentao
• Black Keith L
• Cedars Sinai Medical Center

Inventors

• Yu John S
• Liu Gentao
• Black Keith L

Classifications

• C12N2506/11

  from blood or immune system cells · CPC title

• C12N2501/2304

  Interleukin-4 (IL-4) · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title

• C12N2501/25

  Tumour necrosing factors [TNF] · CPC title